secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059130
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Therapeutics Q1 net loss $19.0M; cash $56.5M; lead candidate CT-0525 prioritized
--------------------------------------------------------------------------------

- Net loss $19.0M for Q1 2024 vs $24.6M in Q1 2023; R&D expenses $17.5M.
- Cash $56.5M as of March 31, 2024; expected to fund operations into Q3 2025.
- Pipeline reprioritization: CT-0525 becomes lead; CT-0508 enrollment ceased; CT-1119 paused; workforce reduced ~37%.
- Initial CT-0525 Phase 1 data expected by year-end 2024; preclinical fibrosis data presented at ASGCT.
- Appointed Eugene Kennedy as CMO; John Hohneker to Board; Chidozie Ugwumba resigned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924059130/0001104659-24-059130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924059130/tm2413903d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer